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A B S T R A C T
Tumor-induced rickets/osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumors that ectopically
express ﬁbroblast growth factor 23 (FGF23). FGF23 is a bone-derived hormone that regulates serum phosphate
concentrations. Patients with TIO develop hypophosphatemic rickets/osteomalacia due to FGF23 excess and
suﬀer from symptoms such as leg deformities, bone pain, skeletal muscle myopathy, and multiple fractures/
pseudofractures. Usually, successful surgical removal of the causative tumors normalizes serum FGF23 and
phosphate concentrations in patients with TIO. Most FGF23-producing tumors associated with TIO are histo-
logically called phosphaturic mesenchymal tumor, mixed connective tissue variant (PMTMCT). The precise
mechanism by which these tumors ectopically overproduce FGF23 outside of bone is yet to be clariﬁed.
Therefore, we performed an RNA sequencing analysis of a PMTMCT that was found in the left parotid gland of a
patient with TIO. Among the upregulated genes, we focused on Klotho, the protein product of which is a single
pass transmembrane protein that works along with an FGF receptor 1c as a receptor complex for FGF23.
Subsequent histological analysis conﬁrmed the ectopic expression of Klotho in other PMTMCTs. From these
results, we assume that the ectopic expression of Klotho in PTMMCTs enables a positive feedback loop in FGF23
production via the activation of FGF receptor 1c and exacerbates disease manifestations in TIO.
1. Introduction
Tumor-induced rickets/osteomalacia (TIO) is a rare paraneoplastic
syndrome caused by tumors that overproduce ﬁbroblast growth factor
23 (FGF23) (Shimada et al., 2001; Kumar, 2000). FGF23 is a bone-de-
rived hormone that regulates serum phosphate concentrations
(Fukumoto and Martin, 2009). FGF23 reduces phosphate reabsorption
in the proximal renal tubules by downregulating sodium-phosphate
cotransporters. FGF23 also decreases phosphate absorption in the in-
testine by reducing serum active vitamin D: 1,25‑dihydroxyvitamin D
[1,25(OH)2D] levels (Shimada et al., 2004). Therefore, chronic FGF23
excess leads to vitamin D-resistant hypophosphatemia. Adult patients
with TIO suﬀer from symptoms such as bone pain, skeletal muscle
myopathy, and multiple fractures/pseudofractures (Minisola et al.,
2017). Additionally, growth retardation and leg deformities are
common features of patients with childhood-onset TIO (Imel et al.,
2006).
Historically, McCance reported a patient with osteomalacia with
resistance to vitamin D in 1947, which is considered to be the ﬁrst
reported case of TIO (McCance, 1947). Weidner and Santa Cruz de-
scribed 17 cases of mesenchymal tumors that caused osteomalacia or
rickets in 1987 (Weidner and Santa Cruz, 1987). Later, it was revealed
that FGF23 excess is responsible for the pathogenesis of TIO (Shimada
et al., 2001; Kumar, 2000). Moreover, FGF23 excess also leads to sev-
eral congenital hypophosphatemic diseases, such as autosomal domi-
nant hypophosphatemic rickets (ADHR: OMIM #193100) (ADHR
Consortium, 2000) and X-linked hypophosphatemia (XLH; OMIM
#307800) (The HYP Consortium, 1995).
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Most causative tumors for TIO are benign and located in bone or soft
tissue (Folpe et al., 2004), except for a few cases of TIO caused by
malignancies such as colorectal, ovarian, prostate, and thyroid cancers
(Lin et al., 2014; Leaf et al., 2013; Mak et al., 2012; Abate et al., 2016).
These mesenchymal tumors are histologically termed phosphaturic
mesenchymal tumor, mixed connective tissue variant (PMTMCT). The
typical features of PMTMCT are the dense proliferation of spindle-
shaped cells, myxoid areas, chondroid or osteoid-matrix containing
ﬂocculent calciﬁcation, osteoclast-like giant cells, and blood vessels
(Folpe et al., 2004). The majority of PMTMCTs are histologically be-
nign, but a relatively small number of malignant PMTMCTs with distant
metastases have been reported (Morimoto et al., 2014; Nair et al., 2017;
Yavropoulou et al., 2018).
FGF23 is physiologically produced in osteocytes/osteoblasts and
binds to a complex of FGF receptor 1c (FGFR1c) and αKlotho (referred
to as Klotho in this manuscript) to serve its function (Urakawa et al.,
2006; Kurosu et al., 2006). Klotho is a single-pass transmembrane
protein that shares sequence homology with family I beta-glycosidases
(Matsumura et al., 1998). In human, the expression of Klotho is re-
stricted to speciﬁc organs such as the kidney, prostate, placenta, and
parathyroid glands. Considering the ubiquitous expression of FGFR1c,
it is likely that Klotho enables the site-speciﬁc action of FGF23
(Urakawa et al., 2006). Klotho-deﬁcient mice show FGF23 resistance
with a 2000-fold increase in serum FGF23 concentrations compared to
those in wild-type mice (Kuro-o et al., 1997). Moreover, because of the
loss of FGF23 function, Klotho-deﬁcient mice show similar phenotypes
to those of Fgf23-null mice, such as ectopic calciﬁcation, elevated serum
1,25(OH)2D concentrations, and hyperphosphatemia (Kurosu et al.,
2006). Therefore, it is widely accepted that Klotho plays an essential
role in FGF23 signaling.
The regulatory mechanism of FGF23 production in osteocytes/os-
teoblasts is not fully understood. Animal and human studies have
shown that speciﬁc conditions, such as treatment with active vitamin D
(Kolek et al., 2005; Yamamoto et al., 2010; Hansen et al., 2012; Sprague
et al., 2015), phosphate overload (Hori et al., 2016; Perwad et al., 2005;
Antoniucci et al., 2006; Ferrari et al., 2005), and uremia (Stubbs et al.,
2007), upregulate FGF23 transcription in bone and elevate circulating
FGF23 concentrations. Additionally, previous studies of inherited
FGF23-related hypophosphatemic diseases have shown the involve-
ment of several gene products in FGF23 transcription. For example,
inactivating mutations in the phosphate-regulating endopeptidase
homolog, X-linked (PHEX) gene lead to the upregulation of FGF23 pro-
duction in patients with XLH, which is the most prevalent form of ge-
netic FGF23-related hypophosphatemic rickets (Liu et al., 2003).
So far, the precise mechanism of ectopic FGF23 production in tu-
mors that cause TIO is unknown. Recent studies have shown the pre-
sence of FN1-FGFR1 or FN1-FGF1 fusion genes in several tumors that
are causative for TIO. However, the function of these fusion gene pro-
ducts remains unknown (Lee et al., 2015; Lee et al., 2016). Therefore, to
examine the regulatory mechanism of FGF23 production in TIO-related
tumors, we performed an RNA sequencing analysis using the re-
sponsible tumor in the parotid gland from a patient with TIO. Sub-
sequent investigation conﬁrmed the ectopic expression of Klotho in
FGF23-producing tumors, which suggests the involvement of Klotho in
the pathogenesis of TIO.
2. Subjects and methods
2.1. Subjects
We performed RNA sequencing analysis using RNA extracted from a
tumor and the adjacent normal tissue in the parotid gland of a patient
with TIO (Takashi et al., 2017) (case #1). The brief medical history of
the patient is as follows: the patient was a 77-year-old man who had
been suﬀering from progressive pain in the back and the hip joints for
eight years. Laboratory data showing hypophosphatemia and elevated
serum FGF23 concentrations led to the diagnosis of FGF23-related hy-
pophosphatemic osteomalacia. An 18F-FDG-PET/CT scan revealed a
tumor in the left parotid gland. Higher FGF23 concentration in the left
external jugular vein compared to other sites indicated that the tumor
overproduced FGF23. When the tumor was surgically removed, the
patient's serum phosphate concentration returned to the normal range.
The tumor was histologically diagnosed as a PMTMCT with positive
FGF23 staining.
We subsequently enrolled 12 patients with TIO whose formalin-
ﬁxed, paraﬃn-embedded (FFPE) tumor samples were available (cases
#2–#13). Table 1 summarized the characteristics of patients and the
location of the tumors. All the patients were treated with a combination
of alfacalcidol and oral phosphate salts. Biochemical parameters in-
cluding serum albumin, calcium, phosphate, alkaline phosphatase
(ALP), creatinine (Cr), intact parathyroid hormone (iPTH), 1,25(OH)2D,
and urine phosphate and creatinine were collected from the medical
record. These parameters were measured before the surgery. Serum
FGF23 levels were evaluated using an FGF23 ELISA KIT (Kainos, Tokyo,
Japan) that detects only full-length FGF23 (Endo et al., 2008). Although
the reference range for serum FGF23 is 10–50 pg/mL for healthy sub-
jects without chronic kidney disease, FGF23 levels more than 30 pg/mL
are considered abnormally high in patients with hypophosphatemia and
leads to the diagnosis of FGF23-related hypophosphatemia (Endo et al.,
2008). Serum calcium concentrations were corrected by albumin if al-
bumin was<4.0mg/dL. The reference ranges for adults are
8.8–10.1 mg/dL for serum corrected calcium, 2.7–4.6mg/dL for serum
phosphate, 106–332 U/L for serum ALP, 10–65 pg/mL for serum iPTH,
20–60 pg/mL for serum 1,25(OH)2D, and 0.65–1.07mg/dL (men) and
0.46–0.79mg/dL (women) for serum creatinine. The tubular maximum
reabsorption of phosphate per unit of glomerular ﬁltrate (TmP/GFR)
was calculated using serum phosphate, serum creatinine, urine phos-
phate, and urine creatinine concentrations. The reference range for
TmP/GFR is 2.3–4.3 mg/dL.
This study was approved by the institutional review board of the
University of Tokyo. We obtained written informed consent for the RNA
sequencing and opt-out consent for both the immunohistochemical and
RT-PCR analyses of tumor samples.
2.2. RNA sequencing of the parotid tumor
Total RNA was extracted from the fresh frozen parotid gland tumor
and the adjacent normal parotid gland tissue using the NucleoSpin®
RNA kit (Macherey-Nagel, Duren, Germany).
Paired-end sequencing libraries were constructed using the TruSeq
RNA library Prep Kit v2 (Illumina, San Diego, CA). We sequenced the
libraries on a MiSeq system (Illumina, San Diego, CA) using the 300-
cycles MiSeq Reagent Kits v2 (Illumina, San Diego, CA). Data were
analyzed on a CLC genomic workbench v8 (CLC bio Japan, Tokyo,
Japan).
For RT-PCR, total RNA was reverse transcribed to cDNA using the
PrimeScript® RT Master Mix (Takara Bio, Shiga, Japan). We ampliﬁed
100–300 base products of FGF23, Klotho, FGFR1c, and GAPDH cDNA
using the SapphireAmp® Fast PCR Master Mix (Takara Bio, Shiga,
Japan). The primer sets were as follows: 5′-TCTTTGCTTTGGACCCA
CCT-3′ and 5′-CCACTCGAAACCATCCATGA-3′ for Klotho, 5′-ACTGCTG
GAGTTAATACCAC-3′ and 5′-TTCCAGAACGGTCAACCAT-3′ for
FGFR1c, and 5′-TGGCACCGTCAAGGCTGAGA-3′ and 5′-CCAGCATCGC
CCCACTTGAT-3′ for GAPDH. We purchased the primer sets for FGF23
from TaKaRa Bio (HA181049). The primer sets designed to detect fu-
sion genes were as follows: 5′-TCGGGCCCAGATAACAGGATAC-3′ and
5′-GCCTCCAATTCTGTGGTCAGGT-3′ for the FN1-FGFR1 fusion gene
and 5′-TCGGGCCCAGATAACAGGATAC-3′ and 5′-TGCTTTCTGGCCAT
AGTGAGTC-3′ for the FN1-FGF1 fusion gene. PCR conditions were as
follows: 1 min at 94 °C, followed by 35 cycles of 5 s at 98 °C, 5 s at 58 °C,
and 5 s at 72 °C, with a ﬁnal extension for 3min at 72 °C. PCR products
were electrophoresed on a 1% agarose gel containing ethidium bromide
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and visualized with UV light.
2.3. Immunohistochemistry of the tumor samples
Immunohistochemical (IHC) staining was performed using the
Ventana BenchMark automated immunostainer (Ventana benchmark;
Ventana Medical Systems Inc., Tucson, AZ) according to the manufac-
turer's instructions. The primary antibodies used in this study were an
anti-human Klotho monoclonal antibody that detects 55–261 amino
acids of human Klotho (KM2076, Trans Genic Inc., Kobe, Japan) and an
anti-phospho-Erk1/2 antibody that recognizes phospho-p44/42 MAPK
(#4370, Cell Signaling Technology Japan, Tokyo, Japan).
2.4. Analysis of serum Klotho concentrations in the patients
A human soluble alpha-Klotho assay kit (IBL, Gunma, Japan) was
used to measure the serum Klotho concentrations in 11 out of 13 pa-
tients.
2.5. Statistical analysis
The relationships between each biochemical parameter of the pa-
tients and the relationships between serum FGF23 and serum Klotho
concentrations were analyzed using JMP® Pro14.0 (SAS Institute Japan
Ltd., Tokyo, Japan). p values< 0.05 were considered statistically sig-
niﬁcant.
3. Results
3.1. Patient characteristics
We analyzed nine male patients and four female patients with TIO
in our study. Even though all the patients were treated with a combi-
nation of alfacalcidol and oral phosphate salts, seven and ten of 13
patients showed hypocalcemia and hypophosphatemia, respectively
(Table 1). Serum ALP levels were elevated in 10 patients. Eight patients
showed secondary hyperparathyroidism. TmP/GFR levels were lower
than the reference range in all the patients, suggesting that there was an
increase in renal phosphate wasting as a result of FGF23 excess. In fact,
there was a signiﬁcant positive correlation between serum phosphate
levels and TmP/GFR levels (r= 0.6179, p=0.0244). Additionally,
there was a signiﬁcant negative correlation between serum corrected
calcium and ALP (r=−0.4018, p=0.0322). We did not ﬁnd any
signiﬁcant correlation between serum FGF23 and other parameters. At
the same time, there was no signiﬁcant diﬀerence in parameters be-
tween male and female patients other than serum creatinine levels
(Table 1).
3.2. RNA sequencing analysis of the tumor in the parotid gland
We detected several upregulated and downregulated genes in the
parotid gland tumor compared to those in the adjacent normal tissue.
Table 2 shows a list of representative upregulated genes in the tumor.
We could not identify any signiﬁcant fusion genes that involve FGFR1
or FGF1. The RT-PCR analysis conﬁrmed the presence of FGF23, Klotho,
and FGFR1c mRNA in the tumor (Fig. 1).
3.3. Immunohistochemistry of the causative tumors in TIO
Among 13 tumors from patients with TIO, nine tumors were positive
for IHC staining for Klotho (Table 3). In these tumors, spindle-shaped
tumor cells, which are considered the principal source of FGF23 in TIO,
were positive for Klotho staining. Fig. 2 shows the images of tumor cells
positive for Klotho staining (Fig. 2b–j) and those negative for Klotho
staining (Fig. 2k and l), along with a positive control of renal tubular
cells (a). Additionally, 11 of 13 tumors were positive for phospho-Erk1/
2 staining (Fig. 3b–l) as shown in the thyroid follicular cells (Fig. 3a).
3.4. Analysis of serum Klotho concentrations
Serum Klotho concentrations in the 11 patients whose serum sam-
ples were available were between 317 and 2405 pg/mL (no reference
range provided). Serum FGF23 concentrations in the corresponding
Table 2
Representative upregulated genes in an FGF23-producing tumor in the parotid
gland.
Name RPKMa Fold change
Control Tumor
DMP1 0.9545 2411.07 2345
FGF1 0.0298 67.6582 2107
FGF23 0.1497 207.605 1288
MEPE 5.2285 7159.17 1271
SOST 2.4226 3257.41 1248
SFRP4 1.5490 1976.49 1185
Klotho 0.4545 445.978 911
SPP1 12.9661 11,899.7 852
ACP5 0.3211 236.662 684
PHEX 0.1478 104.634 657
MMP9 2.9010 1659.15 531
DMP1, dentin matrix protein 1; FGF1, ﬁbroblast growth factor 1; FGF23, ﬁ-
broblast growth factor 23; MEPE, matrix extracellular phosphoglycoprotein;
SOST, sclerostin; SFRP4, secreted frizzled-related protein 4; SPP1, secreted
phosphoprotein 1; ACP5, acid phosphatase 5, tartrate resistant; PHEX, phos-
phate-regulating endopeptidase homolog, X-linked; MMP9, matrix metallo-
proteinase 9.
a RPKM, reads per kilobase of exon per million mapped reads.
Fig. 1. RT-PCR analysis of a tumor in a parotid gland.
Gel-electrophoresis of RT-PCR products showed the presence of FGF23, Klotho,
FGFR1c mRNA in the tumor. MM, molecular weight marker; RT, reverse tran-
scription.
Table 3
Summary of immunohistochemical and RT-PCR analyses of tumors.
Case Klotho p-Erk
IHC RT-PCR IHC
1 + + +
2 + N.E. +
3 + + +
4 + N.E. +
5 + + +
6 − N.E. +
7 + N.E. +
8 − N.E. +
9 + N.E. +
10 + N.E. N.E.
11 − − N.E.
12 − N.E. +
13 + N.E. +
IHC, Immunohistochemistry; +, positive; −, negative; N.E., not examined.
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patients were between 94 and 5211 pg/mL. There was no signiﬁcant
correlation between serum Klotho and serum FGF23 concentrations
(r= 0.2332, p=0.4902) (Fig. 4).
4. Discussion
In this study, we detected the ectopic expression of Klotho mRNA
and Klotho protein in the FGF23-producing tumors that cause TIO.
First, the result of RNA sequencing analysis showed the upregulation of
Klotho mRNA in a tumor in a parotid gland compared to the adjacent
normal tissue. Second, IHC analysis of the FFPE samples revealed po-
sitive Klotho staining in nine of 13 FGF23-producing tumors. A previous
report by Yavropoulou et al. showed the expression of Klotho mRNA in
an FGF23-producing tumor in the periphery of the ﬁbula (Yavropoulou
et al., 2015). In our study, we conﬁrmed both the expression of Klotho
mRNA and Klotho protein in the majority of tumors in various loca-
tions. When limited organs such as renal tubular cells express Klotho
under physiological conditions, we hypothesize that the ectopic ex-
pression of Klotho in these mesenchymal tumors may be involved in the
pathogenesis of TIO. Although the exact cause and the meaning of
Klotho expression in PMTMCTs are not yet determined, we want to
propose several hypotheses.
First, we conclude that the ectopic expression of Klotho in the tumor
cells may lead to the activation of FGFRs. There is growing evidence
that FGFRs not only serves as a receptor for FGF23 but also regulates
FGF23 production. Wohrle et al. (2011) have shown that FGF9 induces
Fgf23 expression in the rat osteosarcoma cell line UMR-106 cells in vitro,
which suggests that FGF23 is a target of FGFR signaling in bone. Os-
teoglophonic dysplasia (OGD; OMIM #166250) is caused by activating
mutations in the FGFR1 gene (White et al., 2005). It is reported that
some patients with OGD develop FGF23-related hypophosphatemia in
addition to various skeletal complications, such as craniosynostosis,
dwarﬁsm, and characteristic facial features (White et al., 2005). Con-
versely, conditional deletion of Fgfr1 in osteocytes from Hyp mice,
which is a murine model of XLH, has resulted in reduced circulating
FGF23 (Xiao et al., 2014). In addition, pharmacological inhibition of
FGFRs results in transient repression of FGF23 mRNA in bone and a
decrease in serum FGF23 concentrations in Hypmice (Xiao et al., 2014),
which is in turn followed by a compensatory increase in serum FGF23
levels after long-term therapy (Wohrle et al., 2013). Therefore, we
hypothesize that the ectopic expression of Klotho in PMTMCTs helps in
the activation of the FGFR signaling pathway and creates a local posi-
tive feedback loop for FGF23 production (Fig. 5). In other words, ec-
topically expressed Klotho enables the autocrine and paracrine eﬀects
of FGF23. The positive staining with phospho-Erk1/2 (Fig. 3) is in line
with the activation of the FGFR signaling pathway in FGF23-producing
tumor cells.
Second, we conclude that the expression of Klotho in PMTMCTs
may reﬂect the osteoblastic diﬀerentiation of tumor cells. PMTMCTs are
often present in the bone or the soft tissue adjacent to the bone, which
makes it diﬃcult to interpret the results of genetic analysis of such
tumors. In our study, however, we used a tumor in the parotid gland,
which is not mineralized in physiological conditions, to rule out the
possibility of contamination by calciﬁed tissues. Nonetheless, the result
of RNA sequencing analysis showed the upregulation of genes that are
related to osteoblasts and osteocytes (Table 2). Moreover, matrix me-
talloproteinase 9 (MMP9) and acid phosphatase 5, tartrate resistant
(ACP5), which are unique to osteoclasts and macrophages, were also
upregulated. Since it has been shown that bone-forming cells such as
osteoblasts and osteocytes express low amounts of Klotho (Raimann
et al., 2013; Rhee et al., 2011; Komaba et al., 2017), the Klotho ex-
pression in tumor cells may reﬂect the diﬀerentiation of mesenchymal
Fig. 2. Klotho staining of FGF23-producing tumors.
The spindle-shaped tumor cells, which are considered the principal source of FGF23 in PMTMCTs, were positive for Klotho staining in nine of 13 patients. Shown are
the images of tumors with positive Klotho staining (b, case #1; c, case #2; d, case #3; e, case #4; f, case #5; g, case #7; h, case #9; i, case #10; j, case #13) and those
with negative Klotho staining (k, case #8; l, case #12), along with a positive control of renal tubular cells (a). Original magniﬁcation for all photomicrographs is
×400.
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stem cells to osteoblastic lineage cells. Therefore, we hypothesize that a
bone-like microenvironment is created in PMTMCTs. This bone-like
microenvironment could augment FGF23 production in tumor cells.
Klotho, which is also referred to as αKlotho, is considered vital in
the regulation of phosphate homeostasis, while βKlotho is required for
FGF19 and FGF21 signaling (Kurosu and Kuro, 2009). There are dif-
ferent isoforms of Klotho protein: membrane-bound Klotho and soluble
Klotho. Membrane-bound Klotho has a large extracellular domain that
is subjected to ectodomain shedding and is released into the extra-
cellular space as soluble Klotho (Matsumura et al., 1998). Several re-
ports have suggested the involvement of soluble Klotho in the regula-
tion of FGF23 production. Brownstein et al. have reported a patient
with FGF23-related hypophosphatemic rickets who harbored a trans-
location of a chromosome adjacent to the Klotho gene and elevated
serum Klotho concentrations (Brownstein et al., 2008). Additionally,
treatment with an adeno-associated virus that produced Klotho resulted
in increased circulating serum Klotho and caused FGF23-related hy-
pophosphatemia in mice (Smith et al., 2012). However, in our study, no
correlation was found between serum Klotho and FGF23 concentra-
tions. Therefore, we hypothesize that membrane-bound Klotho rather
than soluble Klotho is involved in the mechanism of FGF23 production
Fig. 3. Phospho-Erk staining of FGF23-producing tumors.
Tumor cells were positive for phospho-Erk1/2 staining in 12 of 13 patients (b, case #1; c, case #2; d, case #3; e, case #4; f, case #5; g, case #6; h, case #7; i, case #8;
j, case #9; k, case #12; l, case #13) as well as the positive control of the thyroid follicular cells (a). Original magniﬁcation for all photomicrographs is ×400.
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Fig. 4. Relationships between serum FGF23 and Klotho concentrations in pa-
tients with TIO.
There was no signiﬁcant correlation between serum FGF23 and Klotho con-
centrations in patients with TIO (n= 11).
Fig. 5. Autocrine/paracrine eﬀects of FGF23 in FGF23-producing tumor cells.
Membrane-bound Klotho enables the autocrine and paracrine eﬀects of FGF23.
FGF23 that is secreted from tumor cells binds to a receptor complex of Klotho
and FGFR1c and activates the FGFR signaling pathway to enhance the pro-
duction of FGF23 in tumor cells. The positive feedback loop in the production of
FGF23 and a bone-like microenvironment in PMTMCTs may exacerbate the
disease manifestations in patients with TIO. MAPK, Mitogen-activated Protein
Kinase.
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in PMTMCTs.
A previous study has shown that Klotho promoter lacks common
regulatory elements such as TATA and CAAT boxes, and that DNA
methylation of a CpG island in its promoter region appears to be re-
sponsible for the tissue-speciﬁc expression of the Klotho gene (Xu and
Sun, 2015). We have conducted a methylation analysis using DNA ex-
tracted from tumors to see whether methylation status correlates with
Klotho expression in FGF23-producing tumors. However, we found no
correlation between promoter methylation status and the amount of
Klotho mRNA expression (data not shown). Therefore, we conclude that
DNA methylation does not principally regulate Klotho expression in
FGF23-producing mesenchymal tumors.
The limitations of this study are as follows: First, as we used FFPE
tissues instead of fresh frozen tissues for IHC analysis; the deterioration
of samples over the years might have resulted in negative Klotho
staining in some cases. Second, we could not determine whether the
expression of Klotho and the presence of the FN1-FGFR1 or FN1-FGF1
fusion genes are mutually exclusive or not in FGF23-producing tumors.
We did not detect these fusion genes for the four patients (cases #1, #3,
#5, and #11) whose tumor RNAs were available. The presumed func-
tion of the protein products of the FN1-FGFR1 and FN1-FGF1 fusion
genes is the activation of FGFR1 (Lee et al., 2016). Therefore, the
presence of these fusion genes is not essential for tumors to produce
FGF23 if there are alternative factors that activate FGFR1. In our case,
the ectopic expression of Klotho and the overproduction of FGF1
(Table 2) may cause the activation of the FGFR1 signaling pathway.
Finally, we could not determine the reason for MAPK activation in tu-
mors without Klotho expression in our study (cases #6, #8, and #12 in
Table 3). We have considered that false-negative Klotho staining be-
cause of sample deterioration, or the presence of FN1-FGFR1 or FN1-
FGF1 fusion genes might explain the positive staining with p-Erk in
Klotho negative samples. We will continue to study the mechanism of
MAPK activation in PMTMCTs by using fresh tumor samples in the
future.
In conclusion, we found the ectopic expression of Klotho in FGF23-
producing tumors. Although the precise regulatory mechanism of
Klotho expression in PMTMCTs is not clear, we hypothesize that Klotho
helps to create a local positive feedback loop in the production of
FGF23 through the activation of FGFR1 and exacerbates disease man-
ifestations in patients with TIO. From a clinical perspective, the prob-
able involvement of the FGFR signaling pathway in the pathogenesis of
TIO justiﬁes the application of FGFR inhibitors in patients with re-
fractory TIO. Although the complete resection of tumors is always the
optimal treatment for TIO, the results of our study suggest that patients
without surgical indication suﬀering from unresectable, residual, or
metastatic lesions may beneﬁt from FGFR inhibitors.
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